Literature DB >> 10591176

Toxic MHC class II beta chains.

N Labrecque1, L Madsen, L Fugger, C Benoist, D Mathis.   

Abstract

Mesh：

Substances：

Year:  1999        PMID： 10591176     DOI： 10.1016/s1074-7613(00)80126-0

Source DB:  PubMed          Journal:  Immunity        ISSN： 1074-7613            Impact factor:   31.745


× No keyword cloud information.
  6 in total

1.  Invariant chain induces B cell maturation in a process that is independent of its chaperonic activity.

Authors:  Didi Matza; Frida Lantner; Yoel Bogoch; Liat Flaishon; Rami Hershkoviz; Idit Shachar
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

Review 2.  Significance of MHC class II haplotypes and IgG Fc receptors in SLE.

Authors:  Sachiko Hirose; Yi Jiang; Hiroyuki Nishimura; Toshikazu Shirai
Journal:  Springer Semin Immunopathol       Date:  2006-09-14

3.  MHC class II cell-autonomously regulates self-renewal and differentiation of normal and malignant B cells.

Authors:  Julia Merkenschlager; Urszula Eksmond; Luca Danelli; Jan Attig; George R Young; Carla Nowosad; Pavel Tolar; George Kassiotis
Journal:  Blood       Date:  2019-01-30       Impact factor: 22.113

4.  Dissection of the role of MHC class II A and E genes in autoimmune susceptibility in murine lupus models with intragenic recombination.

Authors:  Danqing Zhang; Keishi Fujio; Yi Jiang; Jingyuan Zhao; Norihiro Tada; Katsuko Sudo; Hiromichi Tsurui; Kazuhiro Nakamura; Kazuhiko Yamamoto; Hiroyuki Nishimura; Toshikazu Shira; Sachiko Hirose
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-10       Impact factor: 11.205

Review 5.  Invariant Chain Complexes and Clusters as Platforms for MIF Signaling.

Authors:  Robert Lindner
Journal:  Cells       Date:  2017-02-10       Impact factor: 6.600

6.  The intramembrane protease SPPL2a promotes B cell development and controls endosomal traffic by cleavage of the invariant chain.

Authors:  Janna Schneppenheim; Ralf Dressel; Susann Hüttl; Renate Lüllmann-Rauch; Michael Engelke; Kai Dittmann; Jürgen Wienands; Eeva-Liisa Eskelinen; Irm Hermans-Borgmeyer; Regina Fluhrer; Paul Saftig; Bernd Schröder
Journal:  J Exp Med       Date:  2012-12-24       Impact factor: 14.307
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.